Enalare Therapeutics Appoints 3 New Members to Its Board of Directors

The addition of Gino Santini, Bob Yedid, and Joe Petko Significantly Expands Company's Pharmaceutical and Financial Markets Experience and Capabilities

Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions, announced today that it has appointed three new members to its Board of Directors. The Company is very pleased to welcome Gino Santini, Bob Yedid, and Joe Petko to the organization as it launches into an exciting stage of growth and development.

"I am honored to have such incredible industry talent join our board of directors," stated Herm Cukier, Executive Chairman, President, and CEO. "Their collective experiences, capabilities, and networks will be invaluable for our organization as we embark on developing our lead asset ENA-001 for the treatment of acute respiratory depression and plan for further growth and scaling of the organization."

About the New Directors

Gino Santini is a former member of Eli Lilly's Executive Committee and head of Corporate Strategy and Business Development. His prior roles with the Company during a career spanning nearly three decades included being President of US Operations, President of the Women's Health Franchise, and various leadership positions across multiple international regions. Mr. Santini serves on various public and private board of directors including Horizon Pharmaceuticals, Intercept Pharmaceuticals, and Collegium Pharmaceuticals. He holds a degree in Mechanical Engineering from the University of Bologna and an M.B.A. from the Simon School of Business, University of Rochester.

Bob Yedid is currently a Managing Director at LifeSci Advisors helping biopharma clients achieve optimal valuation through their relationships with institutional investors. Previously, Bob was a Portfolio Manager and Senior Research Analyst at Principled Capital with responsibility for all health care investing. Before joining Principled, he was a Vice President at Warburg Pincus, one of the world's largest private equity and venture capital firms, investing in health care. During his time at WP, Bob was a member of the Board of Directors of The Medicines Company (MDCO) and Eurand international. He also spent 15 years in investment banking, including serving as Managing Director in Healthcare Finance Group at Bear Stearns & Co. working on capital markets and M&A transactions in excess of $5.0 billion. He is currently a member of the Board of Directors at Vaxart, a vaccines company. Mr. Yedid earned a BA in Economics from Yale University and an MBA from Stanford University Graduate School of Business.

Joe Petko CFA, has been with Ashford Capital Management for more than 20 years and currently serves as Managing Director, Vice President and Co-CIO. His expertise is investing in high potential and high-quality, small-cap public companies. Previously, Joe held a series of roles with increasing responsibility within Merck's Finance and Corporate Development organizations. Mr. Petko received his BBA in Accounting from the Wharton School at the University of Pennsylvania and an MBA in Finance from Lehigh University.

About Enalare Therapeutics Inc.

Enalare Therapeutics Inc. is a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions including respiratory depression caused by drug overdose, post-surgery, and COVID-19. The Company is planning to initiate pivotal studies in the US for its lead compound ENA-001 in the near term.

###

Contact:

Morgan Wagner

Investor Relations

mwagner@enalare.com

Source: Enalare Therapeutics

Share:


Categories: Pharmaceuticals and Biotech

Tags: Board of Directors, Bob Yedid, Enalare, Enalare Therapeutics, Gino Santini, Joe Petko, Respiratory Depression


About Enalare Therapeutics

View Website

Enalare Therapeutics Inc. is a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions.